Thermo Fisher Scientific (TMO) has been the subject of considerable market activity over the past fiscal year. The company's performance in China was stable, with year-over-year sales experiencing no significant change. Major financial institutions and asset managers, such as M&T Bank Corp and Virtu Financial LLC, have increased their holdings in TMO. Thermo Fisher has also demonstrated strong financial dynamics, completing a $1 billion share buyback. Still, some insiders have shown caution, disposing $2.3 million worth of company shares. Despite experiencing some stock volatility, Thermo Fisher is positioned well for the AI, growth, and low rates era, according to UBS. Thermo Fisher also reported Q3 2024 results, which exceeded estimates, pointing towards a strong fiscal outlook. There have also been several strategic moves made by Thermo Fisher, including the transfer of commercial sample management business from Knipper Health and signing a partnership with Mainz Biomed. However, the company's stock fell recently, despite outperforming the market. Lastly, Thermo Fisher experienced some struggles with sales at two key units, impacting their profit and revenue.
Thermo Fisher Scientific TMO News Analytics from Wed, 24 Apr 2024 07:00:00 GMT to Sat, 21 Dec 2024 10:15:31 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -3
